DiabetesPro SmartBrief

Reading this on a mobile device? Try our optimized mobile version here: https://r.smartbrief.com/resp/dTsqCfbwoceNgrtFqHIe

October 4, 2012

News for diabetes health professionals

Diabetes in Focus

Studies back linagliptin's efficacy in glucose control
Four studies presented at the European Association for the Study of Diabetes meeting showed linagliptin alone or in combination with other diabetes drugs or basal insulin treatment significantly improved blood glucose levels without increasing the risk of hypoglycemia or weight gain in adults and elderly patients with type 2 diabetes. One study also showed linagliptin therapy reduced albuminuria in type 2 diabetes patients with early nephropathy. Healio/Endocrine Today (10/2)

Gastric bypass leads to diabetes remission in study
Seventy-nine percent of patients with short-duration type 2 diabetes who underwent Roux-en-Y gastric bypass surgery attained disease remission, while 39% of those who had the disease for more than eight years were able to reverse diabetes, a study revealed. Researchers also found 73% of patients with short-term diabetes and 21% of those with long-term diabetes were able to discontinue their medications. The results were presented at the European Association for the Study of Diabetes meeting. InternalMedicineNews.com (10/2)

Diabetes raises risk of death due to pulmonary edema
Men with diabetes were nearly three times as likely to die of pulmonary edema, while women with diabetes had a nearly fivefold increased risk of dying from the condition compared with control groups without diabetes, according to a study presented at the European Association for the Study of Diabetes meeting. MedPage Today (free registration) (10/3)

Diabetes drug empagliflozin reduces blood pressure in 2 trials
Data from two clinical trials showed the SGLT-2 inhibitor empagliflozin, developed by Eli Lilly and Co. and Boehringer Ingelheim, helped lower blood pressure when used alone or in addition to metformin in adult type 2 diabetes patients. Reuters (10/2)

High-risk patients benefit from diabetes drug canagliflozin
Two late-stage studies found that adding Johnson & Johnson's diabetes drug candidate canagliflozin to standard or existing therapy reduced blood glucose for the most vulnerable patients, including those at high risk of heart disease and older people who struggle to control blood glucose. Bloomberg Businessweek (10/2)

Nutrition & Wellness

Study: Mediterranean diet outperforms low-carb, low-fat diets
Data on 322 moderately obese participants showed those who followed a Mediterranean diet lost and kept off nearly seven pounds over the course of six years, compared with 3.7 pounds in the low-carb group and 1.3 pounds in the low-fat group. The results appear in the New England Journal of Medicine. Los Angeles Times/Booster Shots blog (tiered subscription model) (10/3)

Practice Update

"Cybersecure" teaches physician practices about HIPAA
The Office of the National Coordinator for Health IT hopes its free Web-based game called "Cybersecure: Your Medical Practice" will help physician office staff better learn HIPAA privacy and security rules. Staff go through different HIPAA scenarios in the game, losing or gaining exam rooms, office equipment and points based on their answers. American Medical News (free content) (10/1)

Trends & Technology

OpenNotes program is popular with patients, study shows
A study of the OpenNotes program showed 87% of patients opened at least one note and most said that reading their physicians' remarks gave them more control over their care and improved medication adherence. The study, reported in the Annals of Internal Medicine, included 105 primary care physicians and more than 13,000 patients. Some patients had privacy concerns but 99% wanted to continue reading the notes. Doctors did not report feeling limited by making them available. Reuters (10/1)

SmartQuote

I start with the premise that the function of leadership is to produce more leaders, not more followers."

--Ralph Nader,
American political activist, author, lecturer and attorney

Subscriber Tools

Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise

Account Director: Aaron Kern (202) 407-7866